| scholarly article | Q13442814 |
| P50 | author | Eiji Matsuura | Q73476759 |
| Takao Koike | Q73731383 | ||
| P2093 | author name string | Igarashi Y | |
| Yasuda T | |||
| Triplett DA | |||
| P2860 | cites work | Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H) | Q24558202 |
| A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection | Q28207774 | ||
| Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus | Q28261335 | ||
| Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor | Q28320184 | ||
| Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus | Q28365920 | ||
| Phosphorus assay in column chromatography | Q29614973 | ||
| Anticardiolipin antibodies in NZW x BXSB F1 mice. A model of antiphospholipid syndrome | Q33369548 | ||
| Immunology and Clinical Importance of Antiphospholipid Antibodies | Q33379907 | ||
| Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus | Q33458388 | ||
| Anti-phospholipid antibodies | Q33458638 | ||
| The role of surface in the biological activities of trehalose 6,6'-dimycolate. Surface properties and development of a model system | Q34283131 | ||
| Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity | Q36157442 | ||
| Anticardiolipin antibodies--clinical associations | Q36707524 | ||
| Expression of anticardiolipin cofactor, human beta 2-glycoprotein I, by a recombinant baculovirus/insect cell system | Q41545004 | ||
| Molecular definition of human beta 2-glycoprotein I (beta 2-GPI) by cDNA cloning and inter-species differences of beta 2-GPI in alternation of anticardiolipin binding | Q41654634 | ||
| Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics. | Q45239170 | ||
| Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin | Q67866864 | ||
| Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus | Q68008000 | ||
| Measurement of anti-phospholipid antibodies by ELISA using beta 2-glycoprotein I as an antigen | Q68042865 | ||
| Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor | Q68090535 | ||
| Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease | Q68091809 | ||
| What is the "true" antigen for anticardiolipin antibodies? | Q68293539 | ||
| The anticardiolipin syndrome | Q69573545 | ||
| Surface modification and evaluation of some commonly used catheter materials. I. Surface properties | Q71666525 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 457-462 | |
| P577 | publication date | 1994-02-01 | |
| P1433 | published in | Journal of Experimental Medicine | Q3186912 |
| P1476 | title | Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface | |
| P478 | volume | 179 |
| Q34062864 | 'Catastrophic' antiphospholipid syndrome |
| Q33330540 | A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardiolipin and anti-beta2-glycoprotein I antibodies |
| Q37412204 | A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice |
| Q81201365 | A protocol for determination of anticardiolipin antibodies by ELISA |
| Q47764968 | A stable, multi-subunit complex of beta2glycoprotein I. |
| Q33915467 | Accelerated atheroma and anti-beta2-glycoprotein I antibodies |
| Q34354736 | Accelerated atheroma, antiphospholipid antibodies, and the antiphospholipid syndrome |
| Q77367365 | Action of anticardiolipin and antibodies to beta2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death |
| Q77664381 | Activated partial thromboplastin time is a predictive parameter for further miscarriages in cases of recurrent fetal loss |
| Q53588810 | Activation of endothelial cells by antiphospholipid antibodies--a possible mechanism triggering thrombosis in patients with antiphospholipid syndrome. |
| Q30846733 | Analysis of T cell responses to the beta 2-glycoprotein I-derived peptide library in patients with anti-beta 2-glycoprotein I antibody-associated autoimmunity |
| Q43901099 | Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients |
| Q40403484 | Anti-beta 2-glycoprotein I antibodies |
| Q41197423 | Anti-beta 2-glycoprotein I antibody: specificity and clinical significance |
| Q34790028 | Anti-beta 2-glycoprotein I autoantibodies and atherosclerosis |
| Q35215762 | Anti-beta(2)-glycoprotein I antibodies and the antiphospholipid syndrome |
| Q33504706 | Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. |
| Q24561680 | Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids |
| Q53331016 | Anti-beta2-glycoprotein I ELISA: methodology, determination of cut-off values in 434 healthy Caucasians and evaluation of monoclonal antibodies as possible international standards. |
| Q71828169 | Antibodies to beta 2-glycoprotein I and prothrombin in habitual abortion |
| Q77697679 | Antibodies to beta 2-glycoprotein-I: urea resistance, binding specificity, and association with thrombosis |
| Q58418550 | Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome |
| Q78594359 | Anticardiolipin and anti-beta2-glycoprotein-I antibodies in hypertensive disorders of pregnancy |
| Q51017522 | Anticardiolipin antibodies and acute alcoholic intoxication. |
| Q40558488 | Anticardiolipin antibodies in NZW x BXSB F1 mice |
| Q40558462 | Anticardiolipin antibodies: specificity and function |
| Q40399658 | Antigenic specificities of "antiphospholipid" autoantibodies |
| Q41197464 | Antigenic specificities of antiphospholipid autoantibodies: implications for clinical laboratory testing and diagnosis of the antiphospholipid syndrome |
| Q35934717 | Antiphospholipid (Hughes) syndrome |
| Q52659030 | Antiphospholipid Antibodies Alter Cell-Death-Regulating Lipid Metabolites in First and Third Trimester Human Placentae. |
| Q33433833 | Antiphospholipid Antibodies and Associated Clinical Manifestations |
| Q41590581 | Antiphospholipid antibodies and cerebral lupus |
| Q33547975 | Antiphospholipid antibodies and reproduction: the antiphospholipid antibody syndrome. |
| Q73086663 | Antiphospholipid antibodies and the antiphospholipid antibody syndrome |
| Q40506562 | Antiphospholipid antibodies and the antiphospholipid syndrome |
| Q36300619 | Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model |
| Q37358421 | Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein |
| Q28364192 | Antiphospholipid antibodies associated with alcoholic liver disease specifically recognise oxidised phospholipids |
| Q37744837 | Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 MAPK. |
| Q33498510 | Antiphospholipid antibodies in pediatric lupus nephritis |
| Q41682862 | Antiphospholipid antibodies or not? The role of beta 2 glycoprotein 1 in autoantibody-mediated pregnancy loss |
| Q41197523 | Antiphospholipid antibodies, eicosanoids and expression of endothelial cyclooxygenase-2. |
| Q28193967 | Antiphospholipid antibodies: biological basis and prospects for treatment |
| Q36799474 | Antiphospholipid antibodies: laboratory and pathogenetic aspects |
| Q33382848 | Antiphospholipid antibodies: paradigm in transition |
| Q35554909 | Antiphospholipid antibody tests: spreading the net |
| Q41025486 | Antiphospholipid antibody: future developments |
| Q35680777 | Antiphospholipid syndrome infectious origin |
| Q38294180 | Antiphospholipid syndrome: 30 years and our contribution |
| Q73447777 | Antiprothrombin autoantibodies in severe preeclampsia and abortion |
| Q77746573 | Apoptosis and antiphospholipid antibodies |
| Q40558527 | Assays for detection of antiphospholipid antibodies |
| Q81939605 | Association between Val/Leu(247) polymorphism of apolipoprotein H and cerebral infarction in a Chinese population |
| Q35553733 | Association of HLA-DM polymorphism with the production of antiphospholipid antibodies |
| Q37378106 | Atherosclerosis in autoimmune diseases |
| Q34249566 | Autoantibodies associated with rheumatic diseases |
| Q35172086 | Autoantibody-mediated atherosclerosis |
| Q35171667 | Autoimmune disease as a cause of reproductive failure |
| Q37283009 | Autoimmune-mediated atherothrombosis |
| Q37606350 | Autoimmunity, infectious immunity, and atherosclerosis |
| Q40558449 | Beta 2-glycoprotein I. |
| Q33328443 | Beta2 glycoprotein I containing immune-complexes in lupus patients: association with thrombocytopenia and lipoprotein (a) levels |
| Q83219181 | Beta2-glycoprotein I gene polymorphisms Val247Leu and Trp316Ser in Spanish patients with primary antiphospholipid syndrome |
| Q74211615 | Beta2-glycoprotein I-dependent and -independent anticardiolipin antibody in non-obese diabetic (NOD) mice |
| Q77994585 | Beta2-glycoprotein I-dependent anticardiolipin antibody is reactive to both beta2-glycoprotein I/oxidized as well as beta2-glycoprotein I/reduced cardiolipin |
| Q54483428 | Beta2GP-I in the anti phospholipid (Hughes') syndrome--from a cofactor to an autoantigen--from induction to prevention of antiphospholipid syndrome. |
| Q47901692 | Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system |
| Q73264883 | Binding properties of antibodies to prothrombin and beta2-glycoprotein I (beta2-GPI) assayed by ELISA and dot blot |
| Q42096240 | Biotinylation of glycan chains in beta2 glycoprotein I induces dimerization of the molecule and its detection by the human autoimmune anti-cardiolipin antibody EY2C9 |
| Q30580637 | Both kinetic data and epitope mapping provide clues for understanding the anti-coagulant effect of five murine monoclonal antibodies to human beta2-glycoprotein I. |
| Q64948069 | Buffer may be the critical factor in measurement of anti-prothrombin antibody on a gamma-ray-irradiated plate by enzyme-linked immunosorbent assay. |
| Q33330858 | Characteristics and pathogenic role of anti-beta2-glycoprotein I single-chain Fv domains: induction of experimental antiphospholipid syndrome |
| Q44300088 | Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen |
| Q40529762 | Clinical and therapeutic aspects of the antiphospholipid syndrome |
| Q33370780 | Clinical manifestations and antiphosphatidylserine antibodies in patients with systemic lupus erythematosus: is there an association? |
| Q35172196 | Clinical relevance of antiprothrombin antibodies |
| Q33496557 | Clinical significance of phospholipid-dependent anti-beta 2-glycoprotein I (beta 2-GPI) antibodies in systemic lupus erythematosus |
| Q61836178 | Coagulation factor XII activity, but not an associated common genetic polymorphism (46C/T),is linked to recurrent miscarriage |
| Q77291197 | Conformationally altered beta 2-glycoprotein I is the antigen for anti-cardiolipin autoantibodies |
| Q40540320 | Cryptic antiphospholipid autoantibodies and serum co-inhibitors |
| Q40841563 | Current insights into the "antiphospholipid" syndrome: clinical, immunological, and molecular aspects |
| Q72002718 | Detection of anti-bovine ?2-glycoprotein I antibody in sera from patients with antiphospholipid syndrome |
| Q36577371 | Diagnosis of antiphospholipid syndrome |
| Q40043923 | Distinguished effects of antiphospholipid antibodies and anti-oxidized LDL antibodies on oxidized LDL uptake by macrophages |
| Q33330002 | Do antibodies to beta2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome? |
| Q61914569 | Effects of β2-glycoprotein I and monoclonal anticardiolipin antibodies in platelet interaction with subendothelium under flow conditions |
| Q35139987 | Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides |
| Q44892012 | Epitope mapping studies of antiphospholipid antibodies and beta 2-GPI using synthetic peptides |
| Q34380569 | Fluctuation in the Levels of Immunoglobulin M and Immunoglobulin G Antibodies for Cardiolipin and β2-Glycoprotein among Healthy Pregnant Women |
| Q33330798 | Further characterization of antibody and antigen in heparin-induced thrombocytopenia |
| Q34354714 | Genetics of antiphospholipid syndrome |
| Q44510105 | Graves' disease associated with anticardiolipin antibody positivity and acquired protein S deficiency |
| Q22254095 | High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II |
| Q35553532 | High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome |
| Q47900900 | High prevalence of co-factor independent anticardiolipin antibodies in malaria exposed individuals |
| Q64966940 | Human monoclonal anti-phospholipid antibodies selectively bind to membrane phospholipid and beta2-glycoprotein I (beta2-GPI) on apoptotic cells. |
| Q48805163 | Hypoperfusion of brain single photon emission computerized tomography in patients with antiphospholipid antibodies |
| Q37316712 | Immunogenic oxidized low-density lipoprotein/beta2-glycoprotein I complexes in the diagnostic management of atherosclerosis |
| Q33496506 | Immunology of antiphospholipid antibodies and their interaction with plasma proteins |
| Q48001576 | Immunopurification of human beta2-glycorprotein I with a monoclonal antibody selected for its binding kinetics using a surface plasmon resonance biosensor |
| Q37351603 | Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients |
| Q35927360 | Insights into the pathophysiology of the antiphospholipid syndrome provided by atomic force microscopy |
| Q24672569 | Interactions and molecular structure of cardiolipin and β2-glycoprotein 1 (β2-GP1) |
| Q37939730 | International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies |
| Q33369796 | Intravenous immunoglobulin therapy in antiphospholipid syndrome |
| Q34442697 | Investigation of antiphosphatidyl-serine antibody and antiphosphatidyl-inositol antibody in ischemic stroke patients |
| Q33329907 | Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype |
| Q61943926 | LUPUS ANTICOAGULANTS AND ANTIPHOSPHOLIPID ANTIBODIES |
| Q36458164 | Laboratory diagnosis and management challenges in the antiphospholipid syndrome |
| Q43203059 | Laboratory diagnosis of antiphospholipid antibodies |
| Q77521448 | Lipid-protein interactions in blood coagulation |
| Q33502380 | Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset |
| Q38060209 | Metabolomics and ischaemic heart disease. |
| Q36585819 | Molecular and cellular basis for pathogenicity of autoantibodies: lessons from murine monoclonal autoantibodies |
| Q40400869 | Molecular studies on phospholipid-binding sites and cryptic epitopes appearing on beta 2-glycoprotein I structure recognized by anticardiolipin antibodies |
| Q39127887 | My contribution, my dream - a look at the future of APS. |
| Q33497589 | Non beta 2-glycoprotein I cofactors for antiphospholipid antibodies |
| Q58551653 | Obstetric antiphospholipid syndrome |
| Q73267440 | Occurrence of anti-prothrombin and anti-beta2-glycoprotein I antibodies in patients with history of thrombosis |
| Q44138798 | Omega-carboxyl variants of 7-ketocholesteryl esters are ligands for beta(2)-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages |
| Q77796443 | Opposite beta2-glycoprotein I requirement for the binding of infectious and autoimmune antiphospholipid antibodies to cardiolipin liposomes is associated with antibody avidity |
| Q35399567 | Optimising testing for phospholipid antibodies |
| Q36283486 | Oxidized LDL/beta2-glycoprotein I complexes: new aspects in atherosclerosis |
| Q35555260 | Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro |
| Q37625594 | Pathogenic role of anti-endothelial cell antibodies in autoimmune rheumatic diseases |
| Q37721597 | Pathophysiology of beta2-glycoprotein I in antiphospholipid syndrome |
| Q33499192 | Phospholipid binding plasma proteins required for antiphospholipid antibody detection--an overview |
| Q33511345 | Plasma gelsolin facilitates interaction between β2 glycoprotein I and α5β1 integrin |
| Q36951078 | Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature |
| Q40551503 | Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome |
| Q40651854 | Prevalence and clinical significance of IgG isotype anti-beta 2-glycoprotein I antibodies in antiphospholipid syndrome: a comparative study with anticardiolipin antibodies |
| Q47877215 | Prevalence and isotype distribution of antiphospholipid antibodies in unselected Chilean patients with venous and arterial thrombosis |
| Q33372577 | Prevalence of antiphospholipid antibodies in Chilean patients with rheumatoid arthritis. |
| Q33566956 | Prevalence of beta 2-glycoprotein I antibody in systemic lupus erythematosus patients with beta 2-glycoprotein I dependent antiphospholipid antibodies |
| Q47739764 | Prevalence of beta2-glycoprotein I antibody in patients with liver cirrhosis: relationship with beta2-glycoprotein I plasma levels and thrombosis |
| Q49153048 | Real-world practice of obstetricians in respect of assays for antiphospholipid antibodies |
| Q77337523 | Recurrent abortion and moderate or strong antiphospholipid antibody production |
| Q44491239 | Relation of preexisting anti-beta2GPI antibodies to infarct size in a rat model |
| Q37196904 | Relationship and significance between anti-beta2-glycoprotein I antibodies and platelet activation state in patients with ulcerative colitis |
| Q71992271 | Report of the First French Anticardiolipin Antibodies Standardization Workshop |
| Q36287542 | Research around beta 2-glycoprotein I: a major target for antiphospholipid antibodies |
| Q54173101 | Resistance to activated protein C activity of an anti-beta 2-glycoprotein I antibody in the presence of beta 2-glycoprotein I. |
| Q41930841 | Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. |
| Q39931228 | Role of apolipoprotein B100 and oxidized low-density lipoprotein in the monocyte tissue factor induction mediated by anti-β2 glycoprotein I antibodies |
| Q24316919 | Self-interaction of soluble and surface-bound beta2-glycoprotein I and its enhancement by lupus anticoagulants |
| Q77391585 | Serum anti-beta2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients |
| Q47957590 | Solid Phase Immunoassay for the Detection of Anti-β2 Glycoprotein I Antibodies |
| Q73738644 | Specificity of anti-phospholipid antibodies in infectious mononucleosis: a role for anti-cofactor protein antibodies |
| Q46349613 | Standardized measurement of major immunoglobulin class (IgG, IgA, and IgM) antibodies to beta2glycoprotein I in patients with antiphospholipid syndrome |
| Q64964305 | Studies on the interaction of placental anticoagulant protein I, beta 2 glycoprotein 1, and antiphospholipid antibodies in the prothrombinase reaction and in the solid phase anticardiolipin assays. |
| Q28143036 | T cells that are autoreactive to beta2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals |
| Q33766710 | Testing for and clinical significance of anticardiolipin antibodies |
| Q40977408 | The antiphospholipid-protein syndrome |
| Q33497875 | The antiphospholipid/cofactor syndromes: a primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays |
| Q51814798 | The binding site in {beta}2-glycoprotein I for ApoER2' on platelets is located in domain V. |
| Q40898490 | The clinical significance of antiphospholipid antibodies |
| Q41197406 | The concept and classification of antiphospholipid/cofactor syndromes |
| Q48612768 | The first genome-wide association study identifying new susceptibility loci for obstetric antiphospholipid syndrome |
| Q73258238 | The hololipoprotein complex of beta(2)-glycoprotein I and dicaproyl phosphatidylserine |
| Q43713854 | The involvement of CD36 in monocyte activation by antiphospholipid antibodies |
| Q41066141 | The role of beta 2-glycoprotein I in the antiphospholipid syndrome |
| Q47719662 | Thrombogenic properties of antiphospholipid antibodies do not depend on their binding to beta2 glycoprotein 1 (beta2GP1) alone |
| Q42378451 | Thrombomodulatory Effect of Anti-B2-Glycoprotein I Antibodies on Crystalline Annexin A5 on Phospholipid Bilayers, as Observed by Atomic Force Microscopy |
| Q47849141 | Use of various methods for anticardiolipin detection in the updated American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus: comment on the letter by Hochberg |
| Q61711988 | Val/Leu247 and Trp/Ser316 polymorphisms in β2 glycoprotein I and their association with thrombosis in unselected Chilean patients |
| Q35552725 | Value of IgA anticardiolipin and anti-beta2-glycoprotein I antibody testing in patients with pregnancy morbidity |
| Q52927013 | [Antiphospholipid syndrome 2007. Current aspects of laboratory diagnostics and their therapeutic consequences]. |
| Q73361307 | [New targets of antiphospholipid antibodies] |
| Q33497587 | beta 2-Glycoprotein I: target antigen for autoantibodies in the 'antiphospholipid syndrome'. |
| Q74348150 | beta(2)-glycoprotein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis |
| Q35584256 | β2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome. |
Search more.